Brought to you by 
InterMune, Array BioPharma enter hepatitis deal
16 Feb 2017
Executive Summary
InterMune (pulmonary and infectious disease, and cancer therapeutics) and Array BioPharma (specializes in structural biology, chemistry, and informatics) are collaborating to develop a small-molecule drug to treat hepatitis.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
InterMune, Array BioPharma enter hepatitis deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice